close
close

NanoVibronix (STU:56R0) P/E without NRI

NanoVibronix (STU:56R0) P/E without NRI

What is the NanoVibronix PE ratio without NRI?

The P/E ratio without NRI or P/E ratio without non-recurring items is a financial ratio used to compare the market price of a company with its EPS without NRI. Status Today (2024-08-22), the share price of NanoVibronix is 0,52 €. NanoVibronix’s EPS without NRI for the Last twelve months (TTM) ended in June 2024 Was -1,20 €Therefore, NanoVibronix’s P/E ratio excluding NRI for Today Is At a loss.

NanoVibronix’s EPS without NRI for the three months until June 2024 Was -0,23 €. It is EPS without NRI for the Last twelve months (TTM) ended in June 2024 Was -1,20 €.

Away Today (2024-08-22), the share price of NanoVibronix is 0,52 €. NanoVibronix’s Earnings per share (diluted) for the Last twelve months (TTM) ended in June 2024 Was -1,20 €. Therefore, NanoVibronix’s P/E for Today Is At a loss.

NanoVibronix’s

EPS (diluted) for the three months until June 2024 Was -0,23 €. It is EPS (diluted) for the Last twelve months (TTM) ended in June 2024 Was -1,20 €.

NanoVibronix’s EPS (base) for the three months until June 2024 Was -0,23 €. It is EPS (base) for the Last twelve months (TTM) ended in June 2024 Was -1,20 €.


NanoVibronix P/E without NRI historical data

The historical data trend for NanoVibronix’s P/E ratio excluding NRI can be seen below:

* For the Operating Data section: All numbers are indicated by the unit following each term and all currency-related amounts are in USD.
* For other sections: All figures are in millions, except per share, ratio and percent amounts. All currency related amounts are stated in the Company’s respective exchange currency.

NanoVibronix P/E without NRI chart

NanoVibronix annual data
trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 22 December 23 December
P/E without NRI

Get a free 7-day trial

Only for Premium Members Only for Premium Members N/A N/A At a loss At a loss At a loss


Competitive comparison of NanoVibronix’s P/E ratio without NRI

For the Medical devices Sub-Industry: NanoVibronix’s P/E excluding NRI as well as competitors’ market caps and P/E excluding NRI data can be viewed below:

* Competing companies are selected from companies in the same industry, headquartered in the same country and with similar market capitalization. The X-axis shows the market capitalization and the Y-axis shows the maturity value. The larger the dot, the higher the market capitalization. Note that “N/A” values ​​are not shown in the chart.



P/E of NanoVibronix without NRI distribution in the medical device and instrument industry

For the Medical devices and instruments Industry and Healthcare Sector, NanoVibronix’s P/E ratio without NRI distribution charts can be found below:

* The red bar shows where NanoVibronix’s P/E ratio is without NRI.


NanoVibronix P/E without NRI calculation

The P/E ratio without NRI or P/E ratio without non-recurring items is a financial ratio used to compare the market price of a company with its EPS without NRI. Regular P/E can be influenced by Non-business income such as the sale of parts of the company. This can increase dramatically in the current year or quarter. However, it cannot be repeated again and again. Therefore, the P/E ratio without NRI is a more accurate indicator of the valuation than regular P/E.

The P/E ratio of NanoVibronix without NRI for Today is calculated as

P/E without NRI = Share price /

EPS without NRI

= 0.52 / -1,196
= -0.43 (at loss)

The share price of NanoVibronix today is €0.52.
NanoVibronix’s EPS without NRI for the last twelve months (TTM) to June 2024, the quarterly data reported by the company within the last 12 months are added, which amounted to -€1.20.

* For the Operating Data section: All numbers are indicated by the unit following each term and all currency-related amounts are in USD.
* For other sections: All figures are in millions, except per share, ratio and percent amounts. All currency related amounts are stated in the Company’s respective exchange currency.

There are at least three types of P/E ratios used by different investors. They are the last twelve months P/E, Forward P/Eor P/E without NRI. A new P/E based on the inflation-adjusted normalized P/E is called Shiller P/Eafter Yale professor Robert Shiller.

For the P/E ratio without NRI, the reported earnings less one-off items are used.

When calculating P/EThe earnings per share used are the earnings per share for the last 12 months.

For Forward P/Ethe yield is the expected yield for the next twelve months.

For Shiller P/Ethe incomes of the last 10 years are adjusted for inflation and averaged. Since the average of the last 10 years is considered, Shiller P/E is also called PE10.


NanoVibronix (STU:56R0) P/E without NRI statement

The P/E can be thought of as the number of years it takes the company to earn back the price you pay for the stock. For example, if a company earns $2 per share per year and the stock is trading at $30, the P/E is 15. Therefore, it will take 15 years for the company to earn back the $30 you paid for its shares, assuming earnings remain constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it will take fewer years for the company to earn back the price you pay for the stock. If a company’s earnings decline, it will take more years. As a shareholder, you want the company to earn back the price you pay as quickly as possible. Therefore, stocks with lower P/E ratios are more attractive than stocks with higher P/E ratios, as long as the P/E is positive. Even for stocks with the same P/Ethe one with the faster growing business is more attractive.

When a company loses money, P/E becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG ratio. PEG ratio is defined as P/E divided by the growth rate. He believes that a company with a P/E equal to its growth rate is fairly valued. Nevertheless, he said he would rather buy a company that grows 20% annually and P/E of 20, instead of a company that grows by 10% annually and P/E of 10.

Because the P/E measures how long it takes to recoup the price you pay, P/E can be applied to stocks from different industries. That is why it is one of the most important and widely used indicators for evaluating stocks.

Similar to the P/E or PS ratio or Price-earnings ratio or Price-free cash flow ratio The P/E ratio without NRI measures the valuation based on the profitability of the company. This is where it differs from the PB ratio which measures the valuation based on the company’s balance sheet.


Be aware

Investors must be aware that P/E can often be misleading, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical companies have higher profit margins at the peaks of economic cycles. Their profits are high and P/E s are artificially low. It is usually a bad idea to buy a cyclical company when the P/E is low. A better ratio to determine the right time to buy a cyclical company is the PS ratio.


NanoVibronix P/E without NRI Related Terms

Thank you for viewing the detailed NanoVibronix P/E ratio excluding NRI from GuruFocus.com. Please click on the links below to view the pages with related terms.


NanoVibronix Business Description

Traded on other exchanges

address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

NanoVibronix Inc manufactures noninvasive biological response activation devices aimed at biofilm prevention, pain management and wound healing that can be used at home without the assistance of healthcare professionals. The company’s primary products are UroShield, PainShield and WoundShield. Each of the UroShield, PainShield and WoundShield products uses a small, disposable transducer that transmits low frequency, low intensity ultrasound waves designed to repair and regenerate tissue, musculoskeletal and vascular structures and reduce biofilm formation on urinary catheters and associated urinary tract infections. The company generates revenue through direct sales of its products to patients as well as through distribution agreements.

Leave a Reply

Your email address will not be published. Required fields are marked *